On August 8, 2019, Khan, M. Amin published a patent.SDS of cas: 1198284-94-4 The title of the patent was Preparation of spiro-lactam NMDA receptor modulators and uses thereof. And the patent contained the following:
The title compounds I [R1 = (independently) H, alkyl, C(O)alkyl, etc.; q = 0-3; R3 = H, alkyl, C(O)R31, C(O)OR32; R6, if present, = (independently) H, (un)substituted alkyl, OH, halo; m = 0-4; R31 and R32 = (independently) H, (un)substituted alkyl, cycloalkyl] or pharmaceutically acceptable salts and/or stereoisomers thereof, having potency in the modulation of NMDA receptor activity, and therefore useful in the treatment of conditions such as depression and related disorders as well as other disorders, were prepared and/or claimed. E.g., a multi-step synthesis of II, starting from piperidine-4-carboxylic acid, was described. Exemplified compounds I were evaluated in the NMDA receptor agonist assays (data given). Representative compounds I were also tested in the pharmacokinetics assays (data given). Pharmaceutical composition comprising compound I was disclosed. The experimental process involved the reaction of tert-Butyl 1-oxo-2,9-diazaspiro[5.5]undecane-9-carboxylate(cas: 1198284-94-4).SDS of cas: 1198284-94-4
The Article related to spiro lactam pren nmda receptor modulator antidepressant pharmacokinetic, Heterocyclic Compounds (One Hetero Atom): Pyridines and other aspects.SDS of cas: 1198284-94-4
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics